Oddity Tech has constructed a direct-to-consumer platform that leverages site and mobile data to optimize product development, marketing spend and user acquisition. By analyzing browsing patterns and purchase histories, the company has identified high-potential SKUs, prioritized R&D investments and accelerated repeat-purchase rates. Since launch, Oddity’s DTC channels have driven a 45% year-over-year increase in repeat orders, while customer acquisition costs have declined by 18% over the past four quarters.

In November 2025, Oddity introduced its Methodiq telehealth service for dermatological conditions such as acne, hyperpigmentation and eczema. Methodiq combines AI-driven skin analysis with computer vision tracking, offering 28 core products and over 100 personalized treatment plans. The platform taps into a potential addressable market of more than 60 million U.S. consumers, positioning Oddity to capture users seeking alternatives to traditional OTC creams and dermatologist visits.

Oddity’s vertically integrated model has yielded a gross margin of 73.1% in its latest reported quarter, reflecting the premium pricing of its beauty and wellness brands and efficiency gains in supply-chain management. Total revenue grew 67% year-over-year in the third quarter of fiscal 2025, driven by robust demand for its flagship skincare line. Over the same period, repeat-buyer contributions rose to 52% of overall sales, underscoring the stickiness of the company’s customer relationships.

The Voyager Portfolio’s decision to add Oddity Tech hinges on the company’s scalable DTC flywheel and unique telehealth expansion. With a current market capitalization of $2.2 billion and a track record of data-driven brand launches, Oddity is expected to deliver compounding shareholder value as it rolls out additional niche brands. Portfolio managers highlight the parallel to other consumer staples—investing in prevailing consumer habits rather than personal usage—citing tens of millions of beauty-routine customers as a durable growth engine.